A5079852624- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Cutaneous Melanoma Detection and Management
- Childhood Cancer Survivors' Quality of Life
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Neutropenia and Cancer Infections
- Histone Deacetylase Inhibitors Research
- Prostate Cancer Treatment and Research
- Monoclonal and Polyclonal Antibodies Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Cell Adhesion Molecules Research
- Neuroblastoma Research and Treatments
- Genomic variations and chromosomal abnormalities
- Statistical Methods in Clinical Trials
- Nonmelanoma Skin Cancer Studies
- Health Systems, Economic Evaluations, Quality of Life
European Organisation for Research and Treatment of Cancer
2015-2024
Centre Hospitalier Universitaire de Reims
2022
CHR Verviers
2022
Hôpitaux Universitaires de Strasbourg
2022
Centre Hospitalier Universitaire de Grenoble
2022
Queen Fabiola Children's University Hospital
2022
Centre Hospitalier Universitaire de Caen Normandie
2022
Université de Reims Champagne-Ardenne
2022
Ghent University Hospital
2022
Université de Caen Normandie
2022
The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial evaluate as adjuvant therapy in resected, high-risk stage III melanoma.Patients completely resected melanoma were randomly assigned (with stratification according cancer geographic region) receive 200 mg of (514 patients) or placebo (505 intravenously every weeks for total 18 doses (approximately...
On the basis of data from a phase 2 trial that compared checkpoint inhibitor ipilimumab at doses 0.3 mg, 3 and 10 mg per kilogram body weight in patients with advanced melanoma, this evaluated dose who had undergone complete resection stage III melanoma.After cutaneous we randomly assigned them to receive (475 patients) or placebo (476) every weeks for four doses, then months up years until disease recurrence an unacceptable level toxic effects occurred. Recurrence-free survival was primary...
To compare low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for intensive chemotherapy.Two-hundred thirty-three (median age, 70 years; range, 90 years) were enrolled; 53% had poor-risk cytogenetics, the median MDS duration at random assignment was 3 months. Primary end point overall survival (OS). Decitabine (15 mg/m(2)) given intravenously over 4 hours three times a day days 6-week cycles.OS...
We report the results of a prospective study in patients more than 65 years age whom two different therapeutic strategies were compared: immediate intensive-induction chemotherapy (arm A) versus "wait and see" supportive care mild cytoreductive only for relief progressive acute myeloid leukemia (AML)-related symptoms B). The major objective was to compare survival outcome both regimens. Thirty-one on arm A received one or courses daunorubicin, vincristine, cytarabine remission induction...
Purpose To detect a pretreatment gene expression signature (GS) predictive of response to MAGE-A3 immunotherapeutic in patients with metastatic melanoma and investigate its applicability different cancer setting (adjuvant therapy resected early-stage non–small-cell lung [NSCLC]). Patients Methods were participants two phase II studies the recombinant antigen combined an immunostimulant (AS15 or AS02 B ). mRNA from biopsies was analyzed by microarray analysis quantitative polymerase chain...
Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibitors remains unknown.To investigate the association between irAEs and recurrence-free survival (RFS) double-blind EORTC 1325/KEYNOTE-054 clinical trial comparing pembrolizumab therapy placebo for treatment of high-risk stage III melanoma.A total 1019 adults melanoma were randomly assigned on a 1:1 ratio to receive or placebo. Eligible 18 years older complete resection...
To compare single-agent gemtuzumab ozogamicin (GO) with best supportive care (BSC) including hydroxyurea as first-line therapy in older patients acute myeloid leukemia unsuitable for intensive chemotherapy.In this trial, at least 61 years old were centrally randomized (1:1) to receive either a single induction course of GO (6 mg/m(2) on day 1 and 3 8) or BSC. Patients who did not progress after could up eight monthly infusions the immunoconjugate 2 mg/m(2). Randomization was stratified by...
Purpose Adjuvant pegylated interferon alfa-2b (PEG-IFN-α-2b) was approved for treatment of resected stage III melanoma in 2011. Here, we present long-term follow-up results this pivotal trial. Patients and Methods In all, 1,256 patients with were randomly assigned to observation (n = 629) or PEG-IFN-α-2b 627) an intended duration 5 years. Stratification factors microscopic (N1) versus macroscopic (N2) nodal involvement, number positive nodes, ulceration tumor thickness, sex, center....
We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage melanoma. On basis 351 recurrence-free survival (RFS) events at a 1.25-year median follow-up, prolonged RFS (hazard ratio [HR], 0.57; P < .0001) compared placebo. This led approval adjuvant treatment by Medicines Agency US Food Drug Administration. Here, we report an updated...
Active immunization against the tumor-specific MAGE-A3 antigen is followed by a few but impressive and durable clinical responses. This randomized phase II trial evaluated two different immunostimulants combined with protein to investigate whether more robust persistent immune response could be associated increased benefit.Patients MAGE-A3-positive stage III or IV M1a melanoma were randomly assigned receive either AS02B AS15 immunostimulant. Clinical end points toxicity rates of objective...
BACKGROUND: In the previously reported primary analyses of this phase 3 trial, 12 months adjuvant pembrolizumab resulted in significantly longer recurrence- and distant metastasis-free survival than placebo patients with resected high-risk stage III melanoma. To confirm stability these benefits, longer-term data were needed. METHODS: We randomly assigned 1019 to receive 200 mg or intravenously every weeks for a total 18 doses (approximately 1 year) had 15-, 36-, 42-month median follow-up....
PURPOSE AND METHODS Optimization of remission-induction and postremission therapy in elderly individuals with acute myeloid leukemia (AML) was the subject a randomized study patients older than 60 years. Remission-induction chemotherapy compared between daunomycin (DNR) 30 mg/m2 on days 1, 2, 3 versus mitoxantrone (MTZ) 8 3, both plus cytarabine (Ara-C) 100 1 to 7. Following complete remission (CR), received one additional cycle DNR or MTZ were then eligible for second randomization eight...
PURPOSE Patients with primary cutaneous melanoma > or = 1.5 mm in thickness are at high risk of having regional micrometastases the time initial surgical treatment. A phase III international study was designed to evaluate whether prophylactic isolated limb perfusion (ILP) could prevent recurrence and influence survival. PATIENTS AND METHODS total 832 assessable patients from 16 centers entered study; 412 were randomized wide excision (WE) only 420 WE plus ILP melphalan mild hyperthermia....